Literature DB >> 9809064

SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates.

A Sittler1, S Wälter, N Wedemeyer, R Hasenbank, E Scherzinger, H Eickhoff, G P Bates, H Lehrach, E E Wanker.   

Abstract

The mechanism by which aggregated polygins cause the selective neurodegeneration in Huntington's disease (HD) is unknown. Here, we show that the SH3GL3 protein, which is preferentially expressed in brain and testis, selectively interacts with the HD exon 1 protein (HDex1p) containing a glutamine repeat in the pathological range and promotes the formation of insoluble polyglutamine-containing aggregates in vivo. The C-terminal SH3 domain in SH3GL3 and the proline-rich region in HDex1p are essential for the interaction. Coimmunoprecipitations and immunofluorescence studies revealed that SH3GL3 and HDex1p colocalize in transfected COS cells. Additionally, an anti-SH3GL3 antibody was also able to coimmunoprecipitate the full-length huntingtin from an HD human brain extract. The characteristics of the interaction between SH3GL3 and huntingtin and the colocalization of the two proteins suggest that SH3GL3 could be involved in the selective neuronal cell death in HD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809064     DOI: 10.1016/s1097-2765(00)80142-2

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  56 in total

Review 1.  The localization and interactions of huntingtin.

Authors:  A L Jones
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

2.  Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin.

Authors:  S H Li; A L Cheng; H Li; X J Li
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

3.  Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy.

Authors:  V Heiser; E Scherzinger; A Boeddrich; E Nordhoff; R Lurz; N Schugardt; H Lehrach; E E Wanker
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

4.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 5.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

6.  Domain-specific characteristics of the bifunctional key enzyme of sialic acid biosynthesis, UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase.

Authors:  Astrid Blume; Wenke Weidemann; Ulrich Stelzl; Erich E Wanker; Lothar Lucka; Peter Donner; Werner Reutter; Rüdiger Horstkorte; Stephan Hinderlich
Journal:  Biochem J       Date:  2004-12-15       Impact factor: 3.857

7.  Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor.

Authors:  M I Diamond; M R Robinson; K R Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

8.  Modeling Huntington's disease in cells, flies, and mice.

Authors:  S Sipione; E Cattaneo
Journal:  Mol Neurobiol       Date:  2001-02       Impact factor: 5.590

9.  Disruption of the endocytic protein HIP1 results in neurological deficits and decreased AMPA receptor trafficking.

Authors:  Martina Metzler; Bo Li; Lu Gan; John Georgiou; Claire-Anne Gutekunst; Yushan Wang; Enrique Torre; Rebecca S Devon; Rosemary Oh; Valerie Legendre-Guillemin; Mark Rich; Christine Alvarez; Marina Gertsenstein; Peter S McPherson; Andras Nagy; Yu Tian Wang; John C Roder; Lynn A Raymond; Michael R Hayden
Journal:  EMBO J       Date:  2003-07-01       Impact factor: 11.598

10.  Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay.

Authors:  Volker Heiser; Sabine Engemann; Wolfgang Bröcker; Ilona Dunkel; Annett Boeddrich; Stephanie Waelter; Eddi Nordhoff; Rudi Lurz; Nancy Schugardt; Susanne Rautenberg; Christian Herhaus; Gerhard Barnickel; Henning Böttcher; Hans Lehrach; Erich E Wanker
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.